公开(公告)号：US20240294629A1

公开(公告)日：2024-09-05

申请号：US18650552

申请日：2024-04-30

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED

Inventor： Myrna A. MONCK ,  Narendra B. BAM ,  Jennifer DALLY ,  Michelle SPATARA

IPC: C07K16/24 ,  A61P11/02 ,  A61P11/06

CPC classification number: C07K16/244 ,  A61P11/02 ,  A61P11/06 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/90 ,  C07K2317/94

Abstract: The present disclosure relates to compositions for treating interleukin 5 (IL-5) mediated diseases, and related methods.

公开(公告)号：US20240294594A1

公开(公告)日：2024-09-05

申请号：US18573397

申请日：2022-06-23

Applicant: Cytune Pharma ,  Sotio Biotech a.s.

Inventor： Irena Adkins ,  Eva Nedvedová ,  Guy Luc Michel De Martynoff ,  Ulrich Moebius ,  David Béchard ,  Šárka Pechoucková ,  Zuzana Antošová ,  Lenka Kyrych Sadilkova ,  Roger Renzo Beerli ,  Lukas Bammert ,  Lorenz Waldmeier ,  Iva Valentová ,  Simona Hošková

IPC: C07K14/54 ,  A61K39/00 ,  C07K14/715 ,  C07K16/28

CPC classification number: C07K14/5443 ,  C07K14/7155 ,  C07K16/28 ,  C07K16/2818 ,  C07K16/2887 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92 ,  C07K2317/94 ,  C07K2319/30 ,  C07K2319/32

Abstract: The present invention inter alia relates to immunocytokines involving IL-15 superagonists (based on IL-15 and the sushi domain of IL-15Rα) and an antibody. The invention also provides nucleic acids, vectors, methods and medical uses.

公开(公告)号：US12071710B2

公开(公告)日：2024-08-27

申请号：US17058124

申请日：2019-05-31

Applicant: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH

Inventor： Dong-Sik Kim ,  Mi Jung Lee ,  Mi Young Oh ,  Hye-Ji Choi ,  Gil-Jung Kim ,  Shin A Jang ,  Ae Rin Yoon

IPC: C40B40/10 ,  C07K16/00 ,  C07K16/28 ,  C12N15/10

CPC classification number: C40B40/10 ,  C07K16/005 ,  C07K16/28 ,  C12N15/1037 ,  C07K2317/40 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/94

Abstract: The present invention relates to a novel antibody library and an antibody-screening method using same. Having a human sequence-derived specific VH or VL scaffold, the antibody library according to the present invention exhibits high thermodynamic stability and enjoys the advantages of allowing high soluble expression as well as reversible folding. In addition, the antibody according to the present invention includes a variety of rationally controlled CDRs so as to exhibit high specificity and high affinity to all antigens and thus can be advantageously used for selecting an adequate candidate antibody against a target antigen.

公开(公告)号：US12018308B2

公开(公告)日：2024-06-25

申请号：US18132279

申请日：2023-04-07

Applicant: R.P. Scherer Technologies, LLC

Inventor： David Rabuka ,  Gregory W. deHart ,  Patrick Holder ,  Jeanne Baker

IPC: C07K16/00 ,  A61K47/68 ,  C07K16/32 ,  C12N9/02 ,  C12P21/00

CPC classification number: C12P21/005 ,  A61K47/68 ,  A61K47/6889 ,  C07K16/00 ,  C07K16/32 ,  C12N9/0051 ,  C12P21/00 ,  C07K2317/14 ,  C07K2317/40 ,  C12Y108/99

Abstract: The present disclosure provides activated formylglycine-generating enzymes (FGE), methods of producing activated FGE, and their use in methods of producing a protein comprising a formylglycine (FGly) residue. The methods of producing activated FGE, as well as methods of use of activated FGE in producing FGly-containing proteins, include both cell-based and cell-free methods. Compositions and kits that find use, e.g., in practicing the methods of the present disclosure are also provided.

公开(公告)号：US20240059762A1

公开(公告)日：2024-02-22

申请号：US18268192

申请日：2021-12-17

Applicant: Single Cell Technology, Inc.

Inventor： Leyan Tang ,  Allison Schulkins ,  Kimberly Than ,  Chun-Nan Chen

IPC: C07K16/10 ,  A61P31/14 ,  C12N15/63 ,  G01N33/569

CPC classification number: C07K16/1003 ,  A61P31/14 ,  C12N15/63 ,  G01N33/56983 ,  C07K2317/14 ,  C07K2317/24 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/565

Abstract: Provided are antibodies that specifically recognize SARS-CoV-2 N protein. Also provided are compositions comprising the antibodies and uses thereof.

公开(公告)号：US11897954B2

公开(公告)日：2024-02-13

申请号：US17639783

申请日：2021-11-15

Applicant: Astellas Pharma Inc. ,  National Cancer Center

Inventor： Yoshiyuki Tenda ,  Masatoshi Yuri ,  Daisuke Yamajuku ,  Takeshi Tsutsumi ,  Yuko Kusuzaki ,  Hiroki Sasaki ,  Fumiko Chiwaki ,  Masayuki Komatsu

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/28 ,  A61P35/00 ,  C07K16/2809 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/55 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76

Abstract: An objective of the present invention is to provide an anti-TSPAN8/anti-CD3 bispecific antibody and an anti-TSPAN8 antibody usable in treatment or prevention in human. A human monoclonal antibody producing mouse was immunized with a peritoneal disseminated cancer cell isolated from a patient, to obtain an antibody 16B11 and an antibody 16B12 that selectively bind to a peritoneal disseminated cancer cell. These antibodies were anti-TSPAN8 antibodies that bind to the region from amino acid positions 126 to 155 of TSPAN8 and exhibited strong binding activity to TSPAN8 expressed in the peritoneal disseminated cancer cell. Further, an anti-TSPAN8(16B11)-anti-CD3 bispecific antibody produced based on the sequence of 16B11 exhibited a cytotoxic activity against the TSPAN8-expressing cancer cell in vitro, exerted an anti-tumor action on TSPAN8-expressing cancer cell-bearing mice in vivo, and extended the lifetime of peritoneal dissemination model mice.

公开(公告)号：US11858996B2

公开(公告)日：2024-01-02

申请号：US16323980

申请日：2017-08-09

Applicant: Kymab Limited

Inventor： Richard Charles Alfred Sainson ,  Stephen John Arkinstall ,  Jamie Iain Campbell ,  Mohammed Hanif Ali ,  E-Chiang Lee ,  Matthew John McCourt ,  Volker Germaschewski ,  Ian Kirby ,  Miha Kosmac ,  Nahida Parveen ,  Robert Rowlands ,  Gwenoline Borhis

IPC: C07K16/02 ,  A61K39/395 ,  A61P35/00 ,  C07K16/28 ,  A61K47/68 ,  A61K31/282 ,  C07K14/55 ,  C07K16/46 ,  G01N33/50 ,  A61K39/00

CPC classification number: C07K16/2818 ,  A61K31/282 ,  A61K39/395 ,  A61K47/6849 ,  A61P35/00 ,  C07K14/55 ,  C07K16/2827 ,  C07K16/468 ,  G01N33/5026 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/33 ,  C07K2317/40 ,  C07K2317/52 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/73 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/76 ,  C07K2317/92

Abstract: Antibodies that bind ICOS (Inducible T cell Co-Stimulator). Therapeutic use of anti-ICOS antibodies for modulating the ratio between regulatory T cells and effector T cells, to stimulate the immune system of patients, including use in treating cancers. Methods of producing anti-ICOS antibodies, including species cross-reactive antibodies, using transgenic knock-out mice.

公开(公告)号：US11820832B2

公开(公告)日：2023-11-21

申请号：US16481446

申请日：2017-01-27

Applicant: MEMORIAL SLOAN KETTERING CANCER CENTER

Inventor： Nai-Kong V. Cheung ,  Andres Lopez-Albaitero ,  Hong Xu

IPC: C07K16/46 ,  A61K39/395 ,  C07K16/28 ,  C07K16/32 ,  A61P35/02 ,  A61P35/04 ,  A61K45/06 ,  A61K35/17 ,  A61P35/00 ,  A61K39/00

CPC classification number: C07K16/468 ,  A61K35/17 ,  A61K39/3955 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  A61P35/02 ,  A61P35/04 ,  C07K16/2809 ,  C07K16/32 ,  A61K2039/505 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/40 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/76 ,  C07K2317/92

Abstract: Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers.

公开(公告)号：US20230265204A1

公开(公告)日：2023-08-24

申请号：US17996807

申请日：2021-04-23

Applicant: HOFFMANN-LA ROCHE INC.

Inventor： Zhixin SHAO

IPC: C07K16/28 ,  C07K16/18

CPC classification number: C07K16/2887 ,  C07K16/18 ,  C07K16/2809 ,  C07K2317/40 ,  C07K2317/565 ,  C07K2317/31 ,  C07K2317/14

Abstract: The present invention relates to proteins, particularly antibodies such as anti-CD20/anti-CD3 bispecific antibodies and anti α-synuclein antibodies, having monogalactosylated (G1) and digalactosylated (G2) glycans. More particular, the present invention relates to galactosylation engineering to generate proteins with improved therapeutic properties, including proteins with increased titer. Further, the invention relates to a cell culture medium and a mammalian cell as well as methods using said cell culture medium and said mammalian cell for producing said proteins. Moreover, the present invention relates to the use of said antibodies as a medicament such as for the treatment of cancer, particularly cancer associated with B-cells, or Parkinson's disease.

公开(公告)号：US20230250196A1

公开(公告)日：2023-08-10

申请号：US18298933

申请日：2023-04-11

Applicant: City of Hope

Inventor： Andreas Herrmann ,  Hua Yu

IPC: C07K16/46 ,  C12N15/11 ,  A61K47/54 ,  A61K47/68 ,  C07K16/30 ,  A61P35/00 ,  C07K16/40 ,  C07K16/00 ,  A61K38/14 ,  A61K38/00 ,  C07K16/18 ,  A61K39/00

CPC classification number: C07K16/468 ,  C12N15/11 ,  A61K47/549 ,  A61K47/6879 ,  A61K47/6843 ,  A61K47/6851 ,  C07K16/30 ,  A61P35/00 ,  C07K16/40 ,  A61K47/6871 ,  C07K16/00 ,  A61K38/14 ,  A61K38/00 ,  C07K16/18 ,  A61K47/6889 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/77 ,  C07K2317/31 ,  C07K2317/622 ,  C12N2310/315 ,  C07K2317/40 ,  C12N2310/3513 ,  C12N2310/18

Abstract: Provided herein are cell penetrating conjugates. The conjugates include non-cell penetrating proteins connected through a phosphorothioate nucleic acid, wherein the phosphorothioate nucleic acid enhances intracellular delivery of the non-cell penetrating proteins. Also provided are methods and kits including the conjugates provided herein.